secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2026-06-18T20:35:15+00:00
Accession:  0001193125-26-275976
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics stockholders elect four Class II directors, ratify auditor at 2026 annual meeting
--------------------------------------------------------------------------------

- David Zaccardelli, Katie Ellias, David Link, and Andrew Moin elected as Class II directors with 48.3M, 48.3M, 44.1M, and 44.2M votes for, respectively.
- EisnerAmper LLP ratified as independent auditor for FY2026: 59.3M votes for, 3,373 against, 26,798 abstentions.
- Quorum of 59.3M shares (76.12% of outstanding) present at June 18, 2026 meeting.
- Broker non-votes of 10,994,436 on director elections.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000119312526275976/0001193125-26-275976-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000119312526275976/sabs-20260618.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-275976

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer